SCHEMBL341307

SCHEMBL341307

O=c1oc2ccccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 7/20 0.53
MAOB P27338 6/20 0.53
MAPT P10636 6/20 0.53
HPGD P15428 2/20 0.53
CA2 P00918 2/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
HTT P42858 1/20 0.53
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 4/20 0.42
ALOX12 P18054 4/20 0.42
TDP1 Q9NUW8 4/20 0.42
ALOX15 P16050 4/20 0.42
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 3/20 0.41
PKM P14618 2/20 0.41
USP2 O75604 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23704523 0.81 MAOA (0.44) MAOAMAOBMAPTHPGDCA2
SCHEMBL11637378 0.74 MAOA (0.52) MAOAMAOBMAPTHPGDCA2
SCHEMBL9032568 0.73 GPR3 (0.48) MAOAMAOBMAPTHPGDCA2
SCHEMBL869986 0.71 GPR3 (0.40) MAOAMAOBMAPTHPGDCA2
SCHEMBL23240 0.71 GPR3 (0.40) MAOAMAOBMAPTHPGDCA2
SCHEMBL3724121 0.71 ESR2 (0.39) MAOAMAPTHPGDALDH1A1HSD17B10
SCHEMBL5541064 0.71 MAOA (0.63) MAOAMAOBMAPTHPGDCA2
SCHEMBL1091708 0.71 MAOA (0.48) MAOAMAOBMAPTHPGDCA2
SCHEMBL1092088 0.71 MAPT (0.44) MAOAMAOBMAPTHPGDCA2
SCHEMBL2641278 0.71 MAPT (0.48) MAOAMAOBMAPTHPGDCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2887940-B1 INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF UNIV CORNELL (US) 2019-06-05 EP claimed
US-20150196546-A1 INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF CORNELL UNIVERSITY 2015-07-16 US claimed
EP-2887940-A2 INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF Cornell University (US) 2015-07-01 EP claimed
WO-2014031759-A2 INHIBITORS OF CRL4 UBIQUITIN LIGASE AND USES THEREOF CORNELL UNIVERSITY (US) 2014-02-27 WO claimed
JP-5339110-A None JP disclosed
JP-60006680-A None JP disclosed
US-12630504-B2 Phenethylamine derivatives, compositions, and methods of use CYBIN IRL LIMITED (IE) 2026-05-19 US disclosed
US-20240317704-A1 PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE CYBIN IRL LIMITED (IE) 2024-09-26 US disclosed
EP-3555078-B1 BISARYL HETEROCYCLES AS NRF2 ACTIVATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-03-27 EP disclosed
EP-3367820-B1 PREPARATION OF MODIFIED CELLULOSE AND ITS DERIVATIVES INNOTECH MAT LLC (US) 2024-01-24 EP disclosed
EP-4200290-A1 PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Cybin IRL Limited (IE) 2023-06-28 EP disclosed
EP-3224263-B1 USE OF UBIQUITIN-PROTEASOME SYSTEM INHIBITORS FOR TREATMENT OF TUMORS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE-2 BIOXCEL LLC (US) 2023-05-17 EP disclosed
JP-H05339110-A WATER PEST CONTROL AGENT ASAHI DENKA KOGYO KK 1993-12-21 JP disclosed
EP-0278915-B1 DIPHENYLETHYLENE DERIVATIVES CIBA-GEIGY AG (CH) 1991-11-27 EP disclosed
US-4876270-A INSECTICIDES, MITICIDES, PARASITICIDES CIBA-GEIGY CORPORATION (US) 1989-10-24 US disclosed
US-4871762-A CARDIOVASCULAR DISORDERS, ANTIALLERGENS SANKYO COMPANY, LIMITED (JP) 1989-10-03 US disclosed
EP-0278915-A2 Diphenylethylene derivatives CIBA-GEIGY AG (CH) 1988-08-17 EP disclosed
US-4691027-A FOR TREATING CICULATORY DISORDERS AND ALLERGIES SANKYO COMPANY, LIMITED (JP) 1987-09-01 US disclosed
EP-0157603-A2 1, 3-Benzoxathiole derivatives, their use and their preparation SANKYO COMPANY LIMITED (JP) 1985-10-09 EP disclosed
JP-S606680-A BENZOXATHIOL-2-ONE DERIVATIVE AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE SHOWA DENKO KK 1985-01-14 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317704-A1 PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE HTR2C, HTR2A, PNMT MAOA 215/4885MAOB 318/4885MAPT 188/4885
US-12630504-B2 Phenethylamine derivatives, compositions, and methods of use HTR2C, HTR1A, HTR2A MAOA 144/4885MAOB 216/4885MAPT 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.